DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹1,389.30
arrow_upward
+0.19%(+2.70) 1D
Nov 13, 11:19:29 AM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
₹1,380.00
High
₹1,404.00
Low
₹1,380.00
Mkt. cap
1.16T
Avg. vol.
2.33M
Volume
535.40K
Dividend
0.58%
Quarterly dividend
₹2.00
Ex-dividend date
Jul 10, 2026
P/E ratio
41.37
52-wk high
₹1,414.90
52-wk low
₹1,101.00
EPS
₹33.59
Shares outstanding
166.06M
No. of employees
28K
Open
₹1,380.00
High
₹1,404.00
Low
₹1,380.00
Mkt. cap
1.16T
Avg. vol.
2.33M
Volume
535.40K
Dividend
0.58%
Quarterly dividend
₹2.00
Ex-dividend date
Jul 10, 2026
P/E ratio
41.37
52-wk high
₹1,414.90
52-wk low
₹1,101.00
EPS
₹33.59
Shares outstanding
166.06M
No. of employees
28K
News stories
From web sources and news partners
BeInCrypto
·
8 hours ago
S&P 500 Recovered $1 Trillion in 90 Minutes Despite Wider Market Crash
TradingView
·
2 hours ago
Dow, S&P 500, Nasdaq Futures Edge Higher As Markets Attempt To Recover From Nvidia Rout: SLS, MSFT, CADL, MSTR In Focus
Eurasia Business News
·
6 hours ago
Stock Market Today, November 12, 2026: Dow, S&P 500 and Nasdaq Fall After Jensen Huang Resigns
Traders Union
·
7 hours ago
Jake Wujastyk: S&P 500 and ES_F trade within last Thursday's range for a full week
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorHealth Care
IndustryPharmaceutical industry
Websitedrreddys.com